var data={"title":"Factor IX, recombinant human: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor IX, recombinant human: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7769?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-ix-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor IX, recombinant human: Patient drug information&quot;</a> and <a href=\"topic.htm?path=factor-ix-recombinant-human-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Factor IX, recombinant human: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16255881\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>BeneFIX;</li>\n      <li>Ixinity;</li>\n      <li>Rixubis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16255882\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>BeneFix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16255884\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihemophilic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16257752\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Contains <b>only factor IX</b>. Therefore, <b>NOT INDICATED</b> for the treatment of other factors deficiencies (eg, factors II, VII, VIII, and X), hemophilia A patients with inhibitors to factor VIII, reversal of coumarin-induced anticoagulation, and bleeding due to low levels of liver-dependent clotting factors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> IV: Dosage is expressed in units of factor IX activity; dosing must be individualized based on severity of factor IX deficiency, extent and location of bleeding, clinical status of patient, and recovery of factor IX. <b>Refer to product information for specific manufacturer recommended dosing.</b> Alternatively, the World Federation of Hemophilia (WFH) has recommended general dosing for factor IX products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Formula for units required to raise blood level %:</i></b> <b>Note:</b> If patient has severe hemophilia (ie, baseline factor IX level is or presumed to be &lt;1%), then may just use &ldquo;desired factor IX level&rdquo; instead of &ldquo;desired factor IX level <i>increase</i>&rdquo;. On average, the observed recovery for BeneFix is 0.8 units/dL per units/kg in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x reciprocal of observed recovery (as units/kg per units/dL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Alternative dosing (off-label):</b> <b>Note:</b> The following recommendations may vary from those found within prescribing information or practitioner preference.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis:</i> 15 to 30 units/kg/dose twice weekly (Utrecht protocol; WFH [Srivastava 2013]) <b>or</b> 25 to 40 units/kg/dose twice weekly (Malm&ouml; protocol; WFH [Srivastava 2013]); optimum regimen has yet to be defined.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i></p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">2013 World Federation of Hemophilia Treatment Recommendations (When No Significant Resource Constraint Exists):</caption>\n      <col></col>\n      <col></col>\n      <col></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th>\n            <p style=\"text-indent:0em;\">Site of Hemorrhage/Clinical Situation</p></th>\n          <th>\n            <p style=\"text-indent:0em;\">Desired Factor IX Level to Maintain</p></th>\n          <th>\n            <p style=\"text-indent:0em;\">Duration</p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"3\">\n            <p style=\"text-indent:0em;\">\n              <b>Note:</b> Factor IX level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor IX but should be determined based on an assessment of factor IX levels before the next dose.</p></td></tr></tfoot>\n      <tbody valign=\"top\">\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Joint</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">40-60 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">1-2 days, may be longer if response is inadequate</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Superficial muscle/no neurovascular compromise</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">40-60 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">2-3 days, sometimes longer if response is inadequate</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 60-80 units/dL</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 30-60 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1-2 days</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 3-5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>CNS/head</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 60-80 units/dL</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 30 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1-7 days</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 8-21 days</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Throat and neck</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 60-80 units/dL</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 30 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1-7 days</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 8-14 days</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Gastrointestinal</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 60-80 units/dL</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 30 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 7-14 days</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> Not specified</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Renal</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">40 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">3-5 days</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Deep laceration</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">40 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">5-7 days</p></td></tr>\n        <tr>\n          <td rowspan=\"2\">\n            <p style=\"text-indent:0em;\">\n              <b>Surgery (major)</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Preop:</i> 60-80 units/dL</p></td>\n          <td></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i></p>\n            <p style=\"text-indent:0em;margin-left:2em;\">40-60 units/dL</p>\n            <p style=\"text-indent:0em;margin-left:2em;\">30-50 units/dL</p>\n            <p style=\"text-indent:0em;margin-left:2em;\">20-40 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i></p>\n            <p style=\"text-indent:0em;margin-left:2em;\">1-3 days</p>\n            <p style=\"text-indent:0em;margin-left:2em;\">4-6 days</p>\n            <p style=\"text-indent:0em;margin-left:2em;\">7-14 days</p></td></tr>\n        <tr>\n          <td rowspan=\"2\">\n            <p style=\"text-indent:0em;\">\n              <b>Surgery (minor)</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Preop:</i> 50-80 units/dL</p></td>\n          <td></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 30-80 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 1-5 days depending on procedure type</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Continuous infusion (For patients who require prolonged periods of treatment [eg, intracranial hemorrhage or surgery] to avoid peaks and troughs associated with intermittent infusions) (Batorova 2002; Poon 2012; Rickard, 1995; WFH [Srivastava 2013]):</i> <b>Note:</b> Evidence supporting the use of continuous infusion is primarily with BeneFix (Chowdary 2001); however manufacturer&rsquo;s labeling states that safety and efficacy of BeneFIX administration by continuous infusion has not been established: Following initial bolus to achieve the desired factor IX level, initiate 4 to 6 units/kg/hour; adjust dose based on frequent factor assays and calculation of factor IX clearance at steady-state using the following equations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Factor IX clearance (mL/kg/hour) = (current infusion rate in units/kg/hour)/(plasma level in units/<b>m</b>L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">New infusion rate (units/kg/hour) = (factor IX clearance in mL/kg/hour) x (desired plasma level in units/<b>m</b>L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Routine prophylaxis to prevent bleeding episodes in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> IV: Rixubis: 40 to 60 units/kg twice weekly; may titrate dose depending upon age, bleeding pattern, and physical activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16257745\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=factor-ix-recombinant-human-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Factor IX, recombinant human: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Contains <b>only factor IX</b>. Therefore, <b>NOT INDICATED</b> for the treatment of other factors deficiencies (eg, factors II, VII, VIII, and X), hemophilia A patients with inhibitors to factor VIII, reversal of coumarin-induced anticoagulation, and bleeding due to low levels of liver-dependent clotting factors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> IV: Dosage is expressed in units of factor IX activity; dosing must be individualized based on severity of factor IX deficiency, extent and location of bleeding, clinical status of patient, and recovery of factor IX. <b>Refer to product information for specific manufacturer recommended dosing.</b> Alternatively, the World Federation of Hemophilia (WFH) has recommended general dosing for factor IX products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Formula for units required to raise blood level %:</i></b> <b>Note:</b> If patient has severe hemophilia (ie, baseline factor IX level is or presumed to be &lt;1%), then may just use &ldquo;desired factor IX level&rdquo; instead of &ldquo;desired factor IX level <i>increase</i>&rdquo;. On average, the observed recovery for BeneFix is 0.7 units/dL per units/kg in children &lt;15 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents: IV: Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x reciprocal of observed recovery (as units/kg per units/dL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Alternative recommendations (off label):</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Routine prophylaxis to prevent bleeding episodes in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> IV: Rixubis:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;12 years: 60 to 80 units/kg twice weekly; may titrate dose depending upon age, bleeding pattern, and physical activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: 40 to 60 units/kg twice weekly; may titrate dose depending upon age, bleeding pattern, and physical activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16257757\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668606\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; monitor factor IX levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668607\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; monitor factor IX levels. Use with caution due to the risk of thromboembolic complications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242348\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">BeneFIX: 250 units, 500 units, 1000 units, 2000 units, 3000 units [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ixinity: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rixubis: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16255883\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573584\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16257758\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Solution should be infused at room temperature. Safety and efficacy of continuous infusion administration have not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV administration only:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rixubis: For bolus infusion only; maximum rate of administration is 10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BeneFIX: Should be infused <b>slowly over several minutes</b>. Rate of administration should be determined by the response and comfort of the patient. Do not administer as a continuous infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ixinity: Rate of administration should be determined by the comfort of the patient; maximum rate of administration is 10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Per the WFH, infuse by slow IV injection at a rate not to exceed 3 mL/minute (adults) or 100 <b>units</b>/minute (young children); may also administer as a continuous infusion in select patients. Evidence supporting the use of continuous infusion is primarily with BeneFix (Chowdary 2001); however, the safety and efficacy of BeneFIX and Rixubis administration by continuous infusion has not been established. With patients who have had allergic reactions during factor IX infusion, administration of hydrocortisone prior to infusion may be necessary (WFH [Srivstava 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242349\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Factor IX deficiency:</b> Prevention and control of bleeding episodes in patients with factor IX deficiency (hemophilia B [Christmas disease]); perioperative management in patients with hemophilia B; routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (Rixubis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Limitations of use:</b> These products are not indicated for the treatment of other factor deficiencies (eg, factor II, VII, VIII, X), for the treatment of hemophilia A patients with inhibitors to factor VIII, the reversal of coumarin-induced anticoagulation, or for the treatment of bleeding because of low levels of liver-dependent coagulation factors. Ixinity and Rixubis are not indicated for induction of immune tolerance in patients with hemophilia B.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16255858\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor IX may be confused with Factor IX Complex</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242345\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing (3%), chest tightness (2%), thromboembolic complications, thromboembolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (2% to 11%), dizziness (&le;8%), chills (2%), drowsiness (2%), apathy (1%), depression (1%), lethargy (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (2% to 6%), urticaria (3% to 5%), pruritic rash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea (6%), dysgeusia (&le;5%), oral paresthesia (2%), vomiting (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemophilia (lack of efficacy; 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (&le;30%; non-neutralizing)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Influenza (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (2% to 8%), pain at injection site (&le;6%), cellulitis at injection site (2%), injection site phlebitis (2%), discomfort at injection site (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor (2%), limb pain (1%), weakness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal infarction (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea (3%), cough (2%, dry), hypoxia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, fatigue, halitosis, hypotension, nephrotic syndrome (associated with immune tolerance induction), obstructive uropathy, palpitations, peripheral thrombophlebitis, superior vena cava syndrome (neonates), therapeutic response unexpected (inadequate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242351\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Life-threatening, immediate hypersensitivity reactions (including anaphylaxis) to coagulation factor IX, hamster protein, or any component of the formulation; disseminated intravascular coagulation (Rixubis); signs of fibrinolysis (Rixubis).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242343\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: The development of factor IX antibodies (or inhibitors) has been reported with factor IX therapy (usually occurs within the first 10 to 20 exposure days); the risk of severe hypersensitivity reactions occurring may be greater in these patients. When clinical response is suboptimal, the patient has reached a specified number of exposure days, or patient is to undergo surgical procedure, screen for inhibitors. Patients with severe hemophilia compared to those with mild or moderate hemophilia are more likely to develop inhibitors (WFH [Srivastava 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions (including anaphylaxis) may occur; risk is highest during the early phases of initial exposure in previously untreated patients, especially those with high-risk gene mutations. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential for allergic reactions, the initial ~10 to 20 administrations should be performed under appropriate medical supervision. Hypersensitivity reactions have frequently occurred in close temporal association with the development of factor IX inhibitors; patients experiencing allergic reactions should be evaluated for factor IX inhibitors. If hypersensitivity reactions occur, discontinue immediately; in the case of severe allergic reactions, consider the use of alternative hemostatic measures (WFH [Srivastava 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotic syndrome: Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors and a history of allergic reactions. Safety and efficacy in this situation have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Thromboembolism (eg, pulmonary embolism, venous/arterial thrombosis) may occur. Monitor for early signs of thromboembolism and coagulopathy in patients with hepatic disease, fibrinolysis, peri- and postoperative patients, or patients at risk for thromboembolic events or disseminated intravascular coagulation (DIC). The benefit of treatment should be weighed against the risk of complications in patients with DIC or those at risk for DIC or thromboembolic events. Reports of thrombotic events have also been reported in patients receiving continuous infusion through a central venous catheter, including life-threatening superior vena cava syndrome in critically ill neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with extreme caution in patients with hepatic impairment due to the increased risk of thromboembolic complications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hamster protein: May contain trace amounts of Chinese hamster proteins; hypersensitivity to these proteins may develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Clinical response: Response to factor IX administration may vary. If bleeding is not controlled with the recommended dose, determine plasma level of factor IX and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor IX fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369070\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369068\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=88573&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242346\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16255898\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Factor IX concentrations do not change significantly in pregnant women with coagulation disorders and women with factor IX deficiency may be at increased risk of postpartum hemorrhage. Pregnant women should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Prophylaxis may be needed if factor IX concentrations are &lt;50 units/mL at term and treatment should continue for 3 to 5 days postpartum depending on route of delivery. Because parvovirus infection may cause hydrops fetalis or fetal death, a recombinant product is preferred if prophylaxis or treatment is needed. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Chi 2012; Kadir 2009; Lee 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22453579\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if factor IX (recombinant) is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16257763\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Factor IX levels by the one-stage clotting assay (measure 15 minutes after infusion to verify calculated doses (WFH [Srivastava  2013]), aPTT, BP, HR, signs of hypersensitivity reactions, DIC, and thrombosis; screen for factor IX inhibitors if the patient experiences hypersensitivity reaction or when patient is to undergo surgery, if suboptimal response to treatment occurs, if patient is being intensively treated for &gt;5 days within 4 weeks of the last infusion, or at the following intervals ( WFH [Srivastava  2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children: Screen for inhibitors every 5 exposure days until 20 exposure days, every 10 exposure days between 21 to 50 exposure days, and at a minimum of twice a year until 150 exposure days is reached.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults (with &gt;150 exposure days apart from a 6 to 12 monthly review): Screen for inhibitors when suboptimal response occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16256040\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Average normal factor IX levels are 50% to 150%; patients with severe hemophilia B will have levels &lt;1%, often undetectable. Moderate forms of the disease have levels of 1% to 5% while some mild cases may have 5% to 49% of normal factor IX.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16256038\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replaces deficient clotting factor IX. Hemophilia B, or Christmas disease, is an X-linked inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa) in combination with factor VII:C activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242350\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ixinity: 102 to 314 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rixubis: Children &lt;6 years: ~0.3 L/kg; Children &ge;6 years, Adolescents, and Adults: ~0.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: BeneFIX: 14 to 28 hours; Rixubis: 23 to 28 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years, Adolescents, and Adults: Ixinity: 13 to 43 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years, Adolescents, and Adults: Rixubis: ~26 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &gt;15 years and Adults: BeneFIX: 11 to 36 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21663576\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (BeneFIX Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ixinity Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23672676\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Benefiks (UA);</li>\n      <li>Benefix (AR, AT, AU, BE, BG, CN, CO, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HK, HN, HR, HU, IE, IL, IS, IT, JP, KR, LB, LT, LU, MT, NL, NO, PL, QA, RO, RU, SA, SE, SG, SI, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batorova A, Martinowitz U. Continuous infusion of coagulation factors. <i>Haemophilia</i>. 2002;8(3):170-177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/12010406/pubmed\" target=\"_blank\" id=\"12010406\">12010406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    BeneFix (coagulation factor IX [recombinant]) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi C and Kadir RA, &quot;Inherited Bleeding Disorders in Pregnancy,&quot; <i>Best Pract Res Clin Obstet Gynaecol</i>, 2012, 26(1):103-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/22101176/pubmed\" target=\"_blank\" id=\"22101176\">22101176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chowdary P, Dasani H, Jones JAH, et al. Recombinant factor IX (BeneFix&reg;) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia. 2001;7:140-145.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/11260272/pubmed\" target=\"_blank\" id=\"11260272\">11260272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ixinity (coagulation factor IX [recombinant]) [prescribing information]. Baltimore, MD: Cangene Bio Pharma, Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadir R, Chi C, and Bolton-Maggs P, &quot;Pregnancy and Rare Bleeding Disorders,&quot; <i>Haemophilia</i>, 2009, 15(5):990-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/19298378/pubmed\" target=\"_blank\" id=\"19298378\">19298378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CA, Chi C, Pavord SR, et al, &quot;The Obstetric and Gynaecological Management of Women With Inherited Bleeding Disorders-Review With Guidelines Produced by a Taskforce of UK Haemophilia Centre Doctors' Organization,&quot; <i>Haemophilia</i>, 2006, 12(4):301-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/16834731/pubmed\" target=\"_blank\" id=\"16834731\">16834731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poon MC, Card R. Hemophilia management in transfusion medicine. <i>Transfus Apher Sci</i>. 2012;46(3):299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/22503305/pubmed\" target=\"_blank\" id=\"22503305\">22503305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. <i>Haemophilia</i>. 1995;1(suppl 1):8-13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rixubis (coagulation factor IX [recombinant]) [prescribing information]. Westlake Village, CA: Baxalta US Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shibata M, Shima M, Misu H, et al, &quot;Management of Haemophilia B Inhibitor Patients With Anaphylactic Reactions to FIX Concentrates,&quot; <i>Haemophilia</i>, 2003, 9(3):269-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/12694516/pubmed\" target=\"_blank\" id=\"12694516\">12694516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shord SS and Lindley CM, &quot;Coagulation Products and Their Uses,&quot; <i>Am J Health Syst Pharm</i>, 2000, 57(15):1403-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/10938981/pubmed\" target=\"_blank\" id=\"10938981\">10938981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-e47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/22776238/pubmed\" target=\"_blank\" id=\"22776238\">22776238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, &quot;Dose and Response in Haemophilia--Optimization of Factor Replacement Therapy,&quot; <i>Br J Haematol</i>, 2004, 127(1):12-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/15384973/pubmed\" target=\"_blank\" id=\"15384973\">15384973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varon D and Martinowitz U, &quot;Continuous Infusion Therapy in Haemophilia,&quot; <i>Haemophilia</i>, 1998, 4(4):431-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/9873771/pubmed\" target=\"_blank\" id=\"9873771\">9873771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White GC 2nd, Beebe A, and Nielsen B, &quot;Recombinant Factor IX,&quot; <i>Thromb Haemost</i>, 1997, 78(1):261-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-drug-information/abstract-text/9198163/pubmed\" target=\"_blank\" id=\"9198163\">9198163</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 88573 Version 117.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F16255881\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F16255882\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F16255884\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F16257752\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F16257745\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F16257757\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F24668606\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F24668607\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F242348\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F16255883\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573584\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16257758\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F242349\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F16255858\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F242345\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F242351\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F242343\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F16369070\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F16369068\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F242346\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16255898\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F22453579\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F16257763\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F16256040\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16256038\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F242350\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F21663576\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23672676\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/88573|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-ix-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">Factor IX, recombinant human: Patient drug information</a></li><li><a href=\"topic.htm?path=factor-ix-recombinant-human-pediatric-drug-information\" class=\"drug drug_pediatric\">Factor IX, recombinant human: Pediatric drug information</a></li></ul></div></div>","javascript":null}